Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

NHMRC Advises Conditional Use of Puberty Blockers for Gender-Affirming Care

November 16, 2026 Julia Evans – Entertainment Editor Entertainment

Puberty blockers are appropriate for the gender-affirming care of children in certain circumstances, Australia’s largest medical research organisation advised on Monday after a year-long review of international evidence.

Following restrictions enacted by the governments of Queensland and the Northern Territory within their public hospital systems, the commonwealth-backed National Health and Medical Research Council was tasked by the federal government last year to formulate this guidance. Subsequently, the New Zealand administration implemented comparable restrictions, meeting significant pushback from medical professionals and cautions that minors would be adversely affected.

The council’s interim national clinical practice guidelines advise conditional use of puberty suppressants for children. The guidance could put pressure on state and territory governments to consider their positions.

Rejection of alternative approaches

Critics of gender-affirming care championed alternative strategies, like the wait-and-see method, which the council categorically dismissed. It said that withholding care “can affect the young person’s physical and mental health, wellbeing, and ability to function.”

Puberty blockers are a class of drugs used to stop the body producing oestrogen and testosterone. Synthetic hormones are administered in hormone replacement therapy to substitute natural bodily hormones when addressing medical conditions such as endometriosis, gender incongruence, and hormone-sensitive malignancies including prostate and breast cancer.

For decades, cisgender patients have commonly accessed both therapies, which are also subsidized by the Pharmaceutical Benefits Scheme.

New guidelines define gender incongruence and care standards

Children do not need to show distress to receive treatment for gender incongruence under the updated guidelines, which also advise that multidisciplinary teams be established on an individual, case-by-case basis.

Doctors should “prioritise the best interest and wellbeing of the young person and provide care that respects their autonomy,” the advice reads.

According to the guidelines, gender incongruence is the medical expression for a mismatch between an individual’s internal gender and the sex assigned to them at birth. “It is not a mental health disorder,” it says. “Some young people with gender incongruence will also experience significant distress, known as gender dysphoria.”

Since the 1970s, medications known as puberty blockers have been administered to minors for medical issues like precocious puberty. They have been used in gender-affirming care since the 1990s.

Interim advice aligns with existing Australian standards

Australia’s sole existing set of clinical guidelines for practitioners—the AusPATH Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy—is largely consistent with this new advice. The council is an independent statutory agency funded by the commonwealth and is one of the world’s largest medical research organisations.

According to the review, recommendations regarding puberty blockers were formulated by its multidisciplinary gender guideline development committee and backed by a thorough systematic literature review. “Trans and gender-diverse young people experience unjust and avoidable health disparities arising from stigma, discrimination, and barriers to accessing health care,” it said.

Feedback on the draft recommendations, titled Advice on the use of puberty suppressants in the care of trans and gender-diverse people aged under 18, is being accepted through 18 January via a public consultation process. Finalized guidelines covering broader treatment areas, such as gender-affirming hormones, are projected for release in 2028.


Disclaimer: The views and cultural analyses presented in this article are for informational and entertainment purposes only. Information regarding legal disputes or financial data is based on available public records.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • Iain Macmillan Argues Patriots and C.J. Stroud Offer NFL Betting Value
  • L’abbaye aux Dames de Saintes needs a financial boost to secure its youth cultural festival C’Drôles

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service